Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Folia Histochemica et Cytobiologica

Volumn 49, Issue 1, 2011, Pages 153-160

  Hus, Iwona ^a   Tabarkiewicz, Jacek ^a   Lewandowska, Magdalena ^a   Wasiak, Magdalena ^a   Wdowiak, Paulina ^a   Kusz, Maria ^a   Legieć, Monika ^a   Dmoszyńska, Anna ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Chronic myeloid leukemia; Dendric cells; T regulatory cells; Th17 cells; Tyrosine kinase inhibitors

Indexed keywords

B7 ANTIGEN; BOSUTINIB; CD14 ANTIGEN; CD209 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DASATINIB; IMATINIB; INTERLEUKIN 17; INTERLEUKIN 6; T6 ANTIGEN;

ADULT; AGED; ARTICLE; BASOPHIL; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MALE; MONOCYTE; PERIPHERAL LYMPHOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; TREATMENT DURATION;

EID: 79958107512     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0022     Document Type: Article

References (43)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Fazle Akbar SM, Abe M, Yoshida O, Murakami H, Onji M. Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes. Curr Med Chem. 2006;13:3113-3119.
3. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines. 2005;4:699-710.
4. Eisendle K, Lang A, Eibl B et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol. 2003;120 63-73.
5. Deininger MW, Goldman JM, Melo JV et al. The molecular biology of chronic myeloid leukemia. Blood. 2000,96:3343-3356.
6. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828-2837.
7. Fujii S, Shimizu K, Fujimoto K et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999;90:1117-1129.
8. Takahashi T, Tanaka Y, Nieda M et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res. 2003;27:795-802.
9. + chronic myeloid leukaemia. Br J Haematol. 2007;137: 297-306.
10. Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des. 2009;15:1879-1892.
11. Dannull J, Su Z, Rizzieri D, Yang BK et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
12. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
13. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs. 2009;10:543-549.
14. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cy-totoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133-1142.
15. Dong R, Cwynarski K, Entwistle A et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 2003;101: 3560-3567.
16. + peripheral blood progenitor cells. Blood. 2004;103:538-544.
17. Appel S, Rupf A, Weck MM et al. Effects of imatinib on mono-cyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res. 2005;11:1928-1940.
18. Taďeb J, Maruyama K, Borg C, Terme M, Zitvogel L. Ima-tinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood. 2004;103:1966-1967.
19. Westers TM, Janssen JJ, Houtenbos I, Snoijs NC, van de Loos-drecht AA, Ossenkoppele GJ. Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens. Leukemia. 2006;20:154-157.
20. Sato N, Narita M, Takahashi M et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol. 2003;21:67-75.
21. + T-cell tolerance. Blood. 2005;105:1135-1143.
22. Boissel N, Rousselot P, Raffoux E et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesy-late. Leukemia. 2004;18:1656-1661.
23. Wehner R, Wendisch M, Schäkel K et al. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Leukemia. 2006;20:1629-1632.
24. Wang L, Butt NM, Atherton MG, Clark RE. Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. Leukemia. 2004;18:1025-1027.
25. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck--Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
26. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
27. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2007;21:472-479.
28. Wang X, Zheng J, Liu J et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apop-totic and proliferating status in peripheral blood of acute my-eloid leukemia patients. Eur J Haematol. 2005;75:46-476.
29. Szczepanski MJ, Szajnik M, Czystowska M et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15: 3325-3332.
30. Delluc S, Hachem P, Rusakiewicz S et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother. 2009;58:1669-1677.
31. + regulatory T cells in a dose-dependent manner. Int J Oncol. 2007;31:1133-1139.
32. Fei F, Yu Y, Schmitt A et al. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol. 2009;144:195-205.
33. + murine leukemia. Int J Cancer. 2004;110:251-259.
34. - tumors. J Immunol. 2008;181:6955-6963.
35. Romagnani S. Human Th17 cells. Arthritis Res Ther. 2008; 10:206.
36. Wang L, Yi T, Kortylewski M et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457-1464.
37. Benchetrit F, Ciree A, Vives V. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99:2114-2121.
38. Bettelli E, Korn T, Oukka M, Kuchroo VK et al. Induction and effector functions of T(H)17 cells. Nature. 2008;453:1051-1057.
39. Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-beta, interleukin 23 and pro inflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9:650-657.
40. Humlová Z, Klamová H, Janatková I et al. Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol (Praha). 2006;52:47-58.
41. Panteli KE, Hatzimichael EC, Bouranta PK et al. Serum in-terleukin (IL)-1, IL -2, sIL -2Ra, IL -6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Hae-matol. 2005;130:709-715.
42. Thomas X, Hirschauer C, Troncy J et al. Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome. Leuk Lymphoma. 1997;24: 291-300.
43. Wu C, Wang S, Wang F et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 2009;158:199-204.